Arcturus Therapeutics Stock Surges on Positive Phase 2 Clinical Data

Key Facts

1Arcturus Therapeutics shares surged over 6% following the release of positive Phase 2 interim data for its drug ARCT-810.

Arcturus Therapeutics shares surged by more than 6% during Thursday's trading session. The rally followed the company's announcement of positive interim data from its Phase 2 study of ARCT-810, a candidate drug designed to treat Ornithine Transcarbamylase (OTC) deficiency.

ARCT closed at $13.3 on September 23, 2026, after reaching a session high of $14.61 and a low of $13.26. Benzinga reported that the successful clinical trial results serve as a primary value driver for the biotechnology firm's market performance.